Arabic Arabic English English French French German German
dark

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc., announced that they have completed recruitment for the Phase 2 trial, VLA15-221, of Lyme disease vaccine candidate, VLA15. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Two confirmed cases aboard quarantined container ship

Next Post

Nippon Chemiphar Presents Promising Data on Novel Prescription Cough Medicine, Representing Possibly Second New Rx Cough Drug to Enter Market Since 1950s

Related Posts
Total
0
Share